Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial
Titel:
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial
Auteur:
Vanhoutte, Frédéric Liu, Wen Wiedmann, Richard T. Haspeslagh, Liesbeth Cao, Xin Boundy, Keith Aliprantis, Antonios Davila, Michelle Hartzel, Jonathan Li, Jianing McGuire, Mac Ramsauer, Katrin Tomberger, Yvonne Tschismarov, Roland Brown, Deborah D. Xu, Weifeng Sachs, Jeffrey R. Russell, Kevin Stoch, S. Aubrey Lai, Eseng
Verschenen in:
EBioMedicine
Paginering:
Jaargang 75 () nr. C pagina's p.
Jaar:
2022
Inhoud:
Uitgever:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, The Author(s)